Skip to main content
Journal cover image

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.

Publication ,  Journal Article
Gopalakrishnan, S; D'Souza, A; Scott, E; Fraser, R; Davila, O; Shah, N; Gale, RP; Kamble, R; Diaz, MA; Lazarus, HM; Savani, BN; Solh, M ...
Published in: Biol Blood Marrow Transplant
April 2019

The revised International Staging System (R-ISS) combines ISS with genetic markers and lactate dehydrogenase and can prognosticate newly diagnosed multiple myeloma (MM). Early relapse (<24 months) after upfront autologous hematopoietic cell transplantation (AHCT) strongly predicts inferior overall survival (OS). We examined the ability of R-ISS in predicting early relapse and its independent prognostic effect on postrelapse survival after an early relapse. Using the Center for International Blood and Marrow Transplant Research database we identified MM patients receiving first AHCT within 18 months after diagnosis with available R-ISS stage at diagnosis (n = 628). Relative risks of relapse/progression, progression-free survival (PFS), and OS were calculated with the R-ISS group as a predictor in multivariate analysis. Among early relapsers, postrelapse survival was tested to identify factors affecting postrelapse OS. The cumulative incidence of early relapse was 23%, 39%, and 50% for R-ISS I, R-ISS II, and R-ISS III, respectively (P < .001). Shorter PFS and OS were seen with higher stage R-ISS. R-ISS was independently predictive for inferior postrelapse OS among early relapsers, as was the presence of ≥3 comorbidities and the use of ≥2 induction chemotherapy lines. R-ISS stage at diagnosis predicts early post-AHCT relapse and independently affects postrelapse survival among early relapsers.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

April 2019

Volume

25

Issue

4

Start / End Page

683 / 688

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Transplantation Conditioning
  • Recurrence
  • Prognosis
  • Neoplasm Staging
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gopalakrishnan, S., D’Souza, A., Scott, E., Fraser, R., Davila, O., Shah, N., … Hari, P. (2019). Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant, 25(4), 683–688. https://doi.org/10.1016/j.bbmt.2018.12.141
Gopalakrishnan, Sathish, Anita D’Souza, Emma Scott, Raphael Fraser, Omar Davila, Nina Shah, Robert Peter Gale, et al. “Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.Biol Blood Marrow Transplant 25, no. 4 (April 2019): 683–88. https://doi.org/10.1016/j.bbmt.2018.12.141.
Gopalakrishnan S, D’Souza A, Scott E, Fraser R, Davila O, Shah N, et al. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Apr;25(4):683–8.
Gopalakrishnan, Sathish, et al. “Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.Biol Blood Marrow Transplant, vol. 25, no. 4, Apr. 2019, pp. 683–88. Pubmed, doi:10.1016/j.bbmt.2018.12.141.
Gopalakrishnan S, D’Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Apr;25(4):683–688.
Journal cover image

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

April 2019

Volume

25

Issue

4

Start / End Page

683 / 688

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Transplantation Conditioning
  • Recurrence
  • Prognosis
  • Neoplasm Staging
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Humans